TRCT
BTTX

Tower Research Capital (TRC)’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,443
Closed -$4.38K – 6273
2023
Q4 		$4.38K Sell
22,443
-425
-2% -$92 ﹤0.01% 4962
2023
Q3 		$8.37K Buy
22,868
+18,069
+377% +$12.2K ﹤0.01% 4356
2023
Q2 		$5.18K Sell
4,799
-4,347
-48% -$4.21K ﹤0.01% 4851
2023
Q1 		$6K Buy
9,146
+2,636
+40% +$3.1K ﹤0.01% 4912
2022
Q4 		$7K Sell
6,510
-381
-6% -$562 ﹤0.01% 4651
2022
Q3 		$12K Sell
6,891
-7,736
-53% -$14.1K ﹤0.01% 4396
2022
Q2 		$23K Buy
14,627
+14,440
+7,722% +$24.2K ﹤0.01% 3674
2022
Q1 		$0 Sell
187
-3,726
-95% -$12.9K ﹤0.01% 6753
2021
Q4 		$18K Buy
3,913
+2,861
+272% +$23.5K ﹤0.01% 3816
2021
Q3 		$10K Buy
+1,052
New +$10.5K ﹤0.01% 4360

Other funds holding BTTX

CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Tower Research Capital (TRC)'s BTTX Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 22,443 shares — an estimated $4.38K sold.

Tower Research Capital (TRC) first reported a position in BTTX in Q3 2021 and held it in 10 quarters. The position peaked at $23K in Q2 2022. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

  • Tower Research Capital (TRC) reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 22,443 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.38K.
  • Tower Research Capital (TRC) first reported a position in Better Therapeutics, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Better Therapeutics, Inc. Common Stock position peaked at $23K in Q2 2022.
  • 3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.